Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Basal insulin therapy, currently administered either once or twice daily, is a well-established therapy for diabetes, providing a background ... as daily dosing with Novo Nordisk's Tresiba ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Korro Bio, Inc. (NASDAQ:KRRO), a pharmaceutical company specializing in preparations with a market capitalization of $285 million, announced today that Vineet Agarwal, the company's Chief Financial ...

The Republican-controlled State Senate has joined the DFL-controlled House to advance a proposed emergency insulin bill. In mid-February, the Minnesota Senate established a plan to give ...

Although he has a long background with this strategy and the ... fueled by strong showings from top-10 holdings Alphabet, Meta, and Novo Nordisk, as well as a much-lesser-known name also in ...

For 80-year-old Brampton resident Myrna Adams, gardening has played a big part in her physical and mental well-being.

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...